Median Survival Time

The median survival time was 4.0 years ( 1.5-8.5 years ) .

中位生存时间4.0年（1.5-8.5年）。

The median survival time of surgical group was 14 months .

手术治疗组7例，无住院死亡，中位生存期14月。

The median survival time was 44 months .

中位生存时间为44个月。

The median survival time of untreated patients is only about 3 months .

未经治疗的脑转移癌患者中位生存时间仅有3个月左右。

The estimation and comparison of survival rate , mean and median survival time from incomplete data

不完全生存数据的生存率、平均生存期、中数生存期的估计和比较

Results The median survival time of the recipients in group A was 10.2 ± 2.2 days .

结果A组大鼠存活时间为10.2±2.2天。

The median survival time was 14 months in the group of chemotherapy alone ( 76 cases );

其中单一化疗组（76例）的中数生存期为14个月；

Median survival time for patients with mRCC is 6 to 10 months .

远处转移患者平均生存时间为6-10个月。

Were underwent single and multiple factors analyses . Results The median survival time of 78 patients was 38 months .

结果78例患者的中位生存期38个月，单因素分析发现年龄，血红蛋白，血清钙离子浓度，血清肌酐与预后相关；

The median survival time of 64 patients underwent local resection was ( 102.2 ± 16.2 ) months .

单纯切除组平均生存期（102.2±16.2）个月。

The median survival time ( MST ) of liver grafts was recorded .

应用三袖套法进行大鼠原位肝移植，观察肝移植物平均存活时间（MST）；

Moreover , median survival time after confirmation of initial relapse was2.6 months .

此外，在证实初期复发后平均存活时间为2.6个月。

The median survival time was5,16,28 months , respectively .

三种手术方式的中位生存期分别为5，16，28个月。

The survival analysis showed that median survival time was 14.80 months in edaravone group and 15.60 months in control group .

生存分析显示，依达拉奉组患者平均生存时间为14.80个月，对照组15.60个月；

The use of radiotherapy alone in patients with an average survival time and median survival time was 13.7469 and 11.3000 .

采用单纯放射治疗的患者平均生存时间和中位生存时间分别为13.7469个月和11.3000个月。

In the control group , median survival time ( MST ) of skin allografts was 9 days .

对照组移植皮肤平均存活时间（MST）为9d；

Results : The overall 5-year survival of the patients was 82.0 % and the median survival time was 100.0 months .

结果：本组盆腔淋巴结阴性患者的五年总体生存率为820%，中位生存时间1000月。

The median survival time vas 12.3 months . The survival rate of 1-year was 43.5 % .

中位生存期为12.3个月，1年生存率为43.5%。

Total 3 , 5-year survival were 62.9 % and 60.2 % respectively , median survival time was 66.2 months .

结果显示，总3、5年生存率分别为62.9%和60.2%，中位生存时间为66.2月。

The unresectable pancreatic cancer patients accept intraoperative radiation therapy could improve the median survival time and improve the quality of life .

对不能手术切除的胰腺癌患者，应用术中放疗对提高中位生存期、改善生活质量有一定作用。

The median survival time of 146 patients with low grade primary tumor of thyroid , breast and prostate was 12 months .

原发于甲状腺、乳腺、前列腺者146例，中位生存时间12月（平均13.3月）；

The median survival time and cumulation proportion survival at 10 days was 25.79 days and 67.86 % respectively in group B ;

人工肝B组中位生存时间是25.79天，10天的累积生存率为67.86%；

Median survival time of the rabbits in groups A , B , C was 22 days , 26 days and 54 days respectively .

A、B、C三组实验兔的中位生存时间分别为22天、26天和54天。

Conclusions That VAD regimen is effective in inductive chemotherapy suggests a good prognosis and the median survival time is 43.1 months .

结论初始VAD方案化疗有效者预后较好，中位生存期可达43.1个月，加用骨膦治疗可延长生存期。

Their median survival time was 26 m. The overall 3 - and 5-year survival rate was 60 % and 38 % , respectively .

中位生存时间为26个月，总3、5年生存率分别为60%、38%。

Because MS-treated group has obvious controlled release effect , the median survival time of MS-treated group is longer than free drug group .

微球治疗组呈现明显的缓释作用，平均生存期明显高于纯药组。

The median survival time in patients whose primary tumor is of gastrointestinal origin or not is 12 and 27 months ( P < 0.01 ), respectively .

原发瘤为胃肠道者与非胃肠道者的中位生存期分别为12个月与27个月（P<0.01）。

Results The overall survival rate of 5 - and 10-year was 45 % and 35 % , respectively , with median survival time of 44 months .

结果全组中位生存时间44个月，5、10年总生存率分别为45%、35%。

Median survival time ( MST ) was 10 months . Median time to progression ( MTTP ) was 8 months .

中位生存时间（MST）为10个月，中位进展时间（MTTP）为8个月。

In surgery plus radiotherapy group were 100.0 % , 80.0 % , and 20.0 % , respectively , with a median survival time of 42 months .

手术加放疗组5例患者的1、3、5年生存率分别为100.0%、80.0%和20.0%，中位生存期为42.0个月。